Table 2.
Best overall tumor response and status after 12 weeks of eribulin treatment
| Soft tissue sarcoma subtype | Patient analysis set | CR | PR | SD | SD (≥11 W)b | PD | NE | ORRc (%) | DCRc (%) | CBRc (%) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SASa | (%) | Imaginga | ||||||||||
| All | 255 | 226 | 0 | 17 | 78 | 23 | 125 | 6 | 7.5 | 42.0 | 17.7 | |
| Leiomyosarcoma | 73 | (28.6) | 69 | 0 | 5 | 29 | 8 | 35 | 0 | 7.2 | 49.3 | 18.8 |
| Liposarcoma | 70 | (27.5) | 60 | 0 | 2 | 28 | 9 | 28 | 2 | 3.3 | 50.0 | 18.3 |
| Dedifferentiated | 41 | 36 | 0 | 0 | 19 | 7 | 16 | 1 | 0.0 | 52.8 | 19.4 | |
| Myxoid | 12 | 11 | 0 | 2 | 5 | 2 | 3 | 1 | 18.2 | 63.6 | 36.4 | |
| Well-differentiated | 7 | 4 | 0 | 0 | 2 | 0 | 2 | 0 | 0.0 | 50.0 | 0.0 | |
| Pleomorphic | 3 | 3 | 0 | 0 | 0 | 0 | 3 | 0 | 0.0 | 0.0 | 0.0 | |
| Unknown | 7 | 6 | 0 | 0 | 2 | 0 | 4 | 0 | 0.0 | 33.3 | 0.0 | |
| Undifferentiated pleomorphic sarcoma | 19 | (7.5) | 17 | 0 | 2 | 2 | 1 | 12 | 1 | 11.8 | 23.5 | 17.6 |
| Angiosarcoma | 14 | (5.5) | 12 | 0 | 1 | 2 | 1 | 9 | 0 | 8.3 | 25.0 | 16.7 |
| Synovial sarcoma | 13 | (5.1) | 13 | 0 | 3 | 3 | 1 | 7 | 0 | 23.1 | 46.2 | 30.8 |
| Rhabdomyosarcoma | 12 | (4.7) | 11 | 0 | 2 | 0 | 0 | 8 | 1 | 18.2 | 18.2 | 18.2 |
| Malignant peripheral nerve sheath tumor | 6 | (2.4) | 5 | 0 | 0 | 0 | 0 | 5 | 0 | |||
| Myxofibrosarcoma | 5 | (2.0) | 4 | 0 | 1 | 1 | 0 | 1 | 1 | |||
| Spindle cell sarcoma | 4 | (1.6) | 4 | 0 | 0 | 0 | 0 | 4 | 0 | |||
| Epithelioid sarcoma | 3 | (1.2) | 3 | 0 | 0 | 2 | 0 | 1 | 0 | |||
| Malignant Solitary fibrous tumor | 3 | (1.2) | 3 | 0 | 0 | 0 | 0 | 3 | 0 | |||
| Desmoplastic small round cell tumor | 2 | (0.8) | 2 | 0 | 0 | 1 | 0 | 1 | 0 | |||
| Phyllodes tumor | 2 | (0.8) | 2 | 0 | 0 | 1 | 0 | 1 | 0 | |||
| Undifferentiated sarcoma | 2 | (0.8) | 2 | 0 | 0 | 1 | 0 | 1 | 0 | |||
| Othersd | 27 | (10.6) | 19 | 0 | 1 | 8 | 3 | 9 | 1 | |||
| L-typee | 143 | 129 | 0 | 7 | 57 | 17 | 63 | 2 | 5.4 | 49.6 | 18.6 | |
| Non-L-typee | 112 | 97 | 0 | 10 | 21 | 6 | 62 | 4 | 10.3 | 32.0 | 16.5 | |
aPatients with imaging data.
bSD ≥11 W represents patients with a treatment period longer than 11 weeks from treatment initiation to when SD was confirmed by imaging assessment.
cORR, DCR, and CBR were not calculated for subtypes with < 10 patients.
dEfficacy in each subtype was as follows: PR, undifferentiated round-cell sarcoma; SD (≥11 W), extra-skeletal myxochondrosarcoma, paraganglioma, and uterine tumor resembling ovarian sex-cord tumor; SD, adenocarcinoma, alveolar soft-part sarcoma, intimal sarcoma, pleomorphic spindle epithelioid sarcoma, and sclerosing epithelioid fibrosarcoma.
eL-type, leiomyosarcoma, liposarcoma; Non-L-type, all other subtypes.
Abbreviations: SAS, safety analysis set; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, objective response rate; DCR, disease control rate; CBR, clinical benefit rate.